[go: up one dir, main page]

JO2981B1 - مركبات دوائية تتضمن أملوديبين ولوسارتان - Google Patents

مركبات دوائية تتضمن أملوديبين ولوسارتان

Info

Publication number
JO2981B1
JO2981B1 JOP/2010/0014A JOP20100014A JO2981B1 JO 2981 B1 JO2981 B1 JO 2981B1 JO P20100014 A JOP20100014 A JO P20100014A JO 2981 B1 JO2981 B1 JO 2981B1
Authority
JO
Jordan
Prior art keywords
amlodipine
losartan
pharmaceutical composition
solid pharmaceutical
sodium
Prior art date
Application number
JOP/2010/0014A
Other languages
English (en)
Inventor
Soo Woo Jong
Hyun Im Ji
Hyun Park Jae
Soo Kim Kyeong
Taek Yim Ho
Ii Kim Yong
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO2981(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of JO2981B1 publication Critical patent/JO2981B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق هذا الاختراع بتركيب صيدلاني صلب من أجل منع ومعالجة الاضطرابات القَلْبِيَّةُ الوِعائِيَّة التي تشمل على أملوديبين واللوسارتان كمكونات نشطة، ومُفَتِّت يكون عبارة عن مزيج من اثنين من العناصر على الاقل تم اختياره من مجموعة تتألف من غليكُولات نشا الصوديوم، صوديوم كروس كارميلوز وكروس بوفيدون، والتي تُظهر مستوى عالي ومستقر من معدلات ذوبان أملوديبين واللوسارتان
JOP/2010/0014A 2009-01-23 2010-01-21 مركبات دوائية تتضمن أملوديبين ولوسارتان JO2981B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090005840 2009-01-23
KR1020090090540A KR101160151B1 (ko) 2009-01-23 2009-09-24 암로디핀 및 로자탄을 함유하는 고형 약제학적 조성물

Publications (1)

Publication Number Publication Date
JO2981B1 true JO2981B1 (ar) 2016-09-05

Family

ID=42306870

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2010/0014A JO2981B1 (ar) 2009-01-23 2010-01-21 مركبات دوائية تتضمن أملوديبين ولوسارتان
JOP/2010/0015A JO3328B1 (ar) 2009-01-23 2010-01-21 مركبات دوائية تتضمن أملوديبين ولوسارتان ذات الاستقرار المحسن

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2010/0015A JO3328B1 (ar) 2009-01-23 2010-01-21 مركبات دوائية تتضمن أملوديبين ولوسارتان ذات الاستقرار المحسن

Country Status (32)

Country Link
US (3) US9161933B2 (ar)
EP (3) EP2413931B1 (ar)
JP (3) JP5658172B2 (ar)
KR (2) KR101232296B1 (ar)
CN (4) CN102292085B (ar)
AR (3) AR070897A1 (ar)
AU (3) AU2009338267B2 (ar)
BR (3) BRPI0924136B8 (ar)
CA (3) CA2749903C (ar)
CL (1) CL2011001781A1 (ar)
CO (3) CO6361914A2 (ar)
CR (3) CR20110448A (ar)
DO (3) DOP2011000229A (ar)
EA (3) EA020103B1 (ar)
EC (1) ECSP11011253A (ar)
ES (3) ES2580777T3 (ar)
HN (2) HN2011002022A (ar)
IL (3) IL214146A0 (ar)
JO (2) JO2981B1 (ar)
MA (3) MA33056B1 (ar)
MX (3) MX349221B (ar)
MY (3) MY173823A (ar)
NI (3) NI201100143A (ar)
NZ (3) NZ594738A (ar)
PE (4) PE20100559A1 (ar)
SA (1) SA110310070B1 (ar)
SG (3) SG173044A1 (ar)
TW (3) TWI404534B (ar)
UA (3) UA102721C2 (ar)
UY (2) UY32389A (ar)
WO (3) WO2010085014A1 (ar)
ZA (3) ZA201106161B (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR102900997B1 (ko) 2019-12-11 2025-12-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
CN115666564B (zh) 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法
WO2025224756A1 (en) * 2024-04-23 2025-10-30 Mestastop Solutions Private Limited Composition, method and use thereof for delaying primary tumor metastasis using amlodipine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
AU2002363087A1 (en) 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
WO2003048135A1 (en) 2001-11-14 2003-06-12 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
MXPA05007876A (es) 2003-01-27 2005-09-21 Hanmi Pharm Ind Co Ltd Camsilato de amlodipino amorfo, estable, proceso para preparar el mismo y composicion para la administracion oral del mismo.
WO2005007046A2 (en) * 2003-07-18 2005-01-27 Pneu Medex Inc. Fluid operated actuators and pneumatic unloading orthoses
EP1653950B1 (en) 2003-07-31 2008-01-09 NicOx S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007001067A2 (en) 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
US20080261958A1 (en) 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
RU2426530C2 (ru) * 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023958A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma

Also Published As

Publication number Publication date
CN102292085A (zh) 2011-12-21
CN102292085B (zh) 2017-01-18
BRPI0924136B8 (pt) 2021-05-25
UA105203C2 (ru) 2014-04-25
EA201170959A1 (ru) 2011-12-30
TWI395583B (zh) 2013-05-11
JP2012515770A (ja) 2012-07-12
CR20110449A (es) 2011-11-10
PE20140978A1 (es) 2014-08-16
CN102292084A (zh) 2011-12-21
DOP2011000230A (es) 2011-10-15
IL214145A0 (en) 2011-08-31
MX2011006008A (es) 2011-06-28
HN2011002022A (es) 2014-02-03
ES2580777T8 (es) 2016-09-22
MX2011006061A (es) 2011-06-24
KR101232296B1 (ko) 2013-02-13
US20110245301A1 (en) 2011-10-06
UY32389A (es) 2010-02-26
EP2413931A1 (en) 2012-02-08
US9161933B2 (en) 2015-10-20
US8673945B2 (en) 2014-03-18
ZA201106162B (en) 2012-10-31
WO2010085014A1 (en) 2010-07-29
SA110310070B1 (ar) 2014-09-02
EA201170958A1 (ru) 2012-01-30
EA019471B1 (ru) 2014-03-31
ECSP11011253A (es) 2011-09-30
AU2009338267B2 (en) 2014-09-18
EP2391365B1 (en) 2014-11-26
CA2749955C (en) 2016-07-26
TW201028151A (en) 2010-08-01
CN102292084B (zh) 2014-01-29
CA2749903A1 (en) 2010-07-29
MY151550A (en) 2014-06-13
ES2526606T3 (es) 2015-01-13
NZ594739A (en) 2013-11-29
US8673944B2 (en) 2014-03-18
TW201031404A (en) 2010-09-01
CA2749957C (en) 2016-07-26
CN105998017A (zh) 2016-10-12
JP5466716B2 (ja) 2014-04-09
NI201100144A (es) 2012-11-06
EP2391348A1 (en) 2011-12-07
UA102720C2 (ru) 2013-08-12
CR20110450A (es) 2011-11-10
SG173046A1 (en) 2011-08-29
UA102721C2 (uk) 2013-08-12
US20110245302A1 (en) 2011-10-06
EP2391365A2 (en) 2011-12-07
AU2009338251A1 (en) 2011-09-15
BRPI0924136A2 (pt) 2017-06-13
MX2011006009A (es) 2011-06-28
JO3328B1 (ar) 2019-03-13
IL214147A (en) 2016-08-31
SG173044A1 (en) 2011-08-29
ZA201106160B (en) 2012-10-31
AU2009338280A1 (en) 2011-09-15
CO6361915A2 (es) 2012-01-20
MY150974A (en) 2014-03-31
JP5660544B2 (ja) 2015-01-28
AU2009338251B2 (en) 2014-03-13
NZ594738A (en) 2013-11-29
MX349221B (es) 2017-07-19
MX345956B (es) 2017-02-28
IL214147A0 (en) 2011-08-31
BRPI0924137A2 (pt) 2019-09-24
ES2505116T3 (es) 2014-10-09
SG173045A1 (en) 2011-08-29
AR070897A1 (es) 2010-05-12
AU2009338267A2 (en) 2011-09-29
EA020103B1 (ru) 2014-08-29
CO6361905A2 (es) 2012-01-20
ES2580777T3 (es) 2016-08-26
WO2010085047A2 (en) 2010-07-29
NZ594740A (en) 2013-11-29
CO6361914A2 (es) 2012-01-20
PE20120428A1 (es) 2012-05-17
MA33058B1 (ar) 2012-02-01
EP2391348A4 (en) 2012-07-25
HK1163539A1 (en) 2012-09-14
WO2010085047A3 (en) 2010-11-04
TWI404534B (zh) 2013-08-11
CL2011001781A1 (es) 2012-03-23
HN2011002020A (es) 2014-02-03
KR20100086921A (ko) 2010-08-02
EP2391365A4 (en) 2012-07-25
JP2012515767A (ja) 2012-07-12
DOP2011000231A (es) 2011-10-15
AR075028A1 (es) 2011-03-02
KR101160151B1 (ko) 2012-06-27
AU2009338280B2 (en) 2014-05-01
DOP2011000229A (es) 2011-10-15
BRPI0924136A8 (pt) 2017-10-03
MX345868B (es) 2017-02-21
CN102292070A (zh) 2011-12-21
EA021763B1 (ru) 2015-08-31
MA33057B1 (ar) 2012-02-01
NI201100145A (es) 2012-08-17
BRPI0924136B1 (pt) 2019-10-15
MY173823A (en) 2020-02-24
KR20100086913A (ko) 2010-08-02
PE20100559A1 (es) 2010-09-12
US20110251245A1 (en) 2011-10-13
JP5658172B2 (ja) 2015-01-21
EP2413931B1 (en) 2016-06-01
AU2009338267A1 (en) 2011-09-15
BRPI0924135A2 (pt) 2016-02-10
AR075027A1 (es) 2011-03-02
CA2749957A1 (en) 2010-07-29
PE20100739A1 (es) 2010-11-19
IL214146A0 (en) 2011-08-31
ZA201106161B (en) 2012-10-31
CA2749903C (en) 2016-09-06
EP2413931A4 (en) 2012-08-08
WO2010085027A1 (en) 2010-07-29
CA2749955A1 (en) 2010-07-29
JP2012515768A (ja) 2012-07-12
EA201170960A1 (ru) 2012-01-30
EP2391348B1 (en) 2014-08-27
NI201100143A (es) 2012-08-17
CR20110448A (es) 2011-11-10
UY32388A (es) 2010-02-26
MA33056B1 (ar) 2012-02-01

Similar Documents

Publication Publication Date Title
JO2981B1 (ar) مركبات دوائية تتضمن أملوديبين ولوسارتان
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MX2012000565A (es) Derivados de triterpeno tipo lupeol como antivirales.
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
IN2012DN01233A (ar)
TNSN08405A1 (en) Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MY155256A (en) Pharmaceutical composition having improved solubility
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
UA89394C2 (uk) Композиція оланзапіну або донепезилу, що розпадається при пероральному прийомі
NO20085214L (no) Nye pyridinanaloger
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
UA108277C2 (ru) Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения
NZ599171A (en) Sulfonamides for the prevention of diabetes
WO2008149201A3 (en) Stable pharmaceutical composition
MX2010011767A (es) Derivados de benzocicloheptano y benzoxepina.
WO2013002578A3 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
TW200735880A (en) Medicinal compositions for preventing or treating heart failure
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor
AU2016219657A1 (en) Stable pharmaceutical composition and methods of using same